BC Week In Review | Oct 24, 2016
Clinical News

CX1739: Preliminary Phase IIa data

In September, RespireRx reported preliminary data from 15 patients who achieved >25% depression of their respiratory rate following an acute IV bolus injection of 1ug/kg remifentanil in the double-blind Stage 1 of a 2-stage, crossover,...
BC Week In Review | Mar 7, 2016
Clinical News

CX1739: Phase IIa start

This month, RespireRx will begin a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIa trial to evaluate 3 dose levels of oral CX1739 in about 18 patients. RespireRx Pharmaceuticals Inc. (OTCQB:RSPI), Glen Rock, N.J.   Product: CX1739...
BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Week In Review | Aug 20, 2012
Company News

Cortex Pharmaceuticals, Pier Pharmaceuticals deal

Cortex merged with Pier in a stock deal. Pier's former shareholders and vendors received about 58 million Cortex common shares, which are valued at about $4.1 million based on Cortex's close of $0.07 on Aug....
BC Week In Review | Oct 31, 2011
Company News

Cortex Pharmaceuticals, Samyang Optics Co. Ltd. deal

The parties signed a memorandum of understanding granting Samyang South Korean rights to CX1739 for neurodegenerative diseases. Samyang will also receive the right of negotiation for rights to CX1846 for neurodegenerative diseases as well as...
BC Week In Review | Mar 21, 2011
Company News

Cortex Pharmaceuticals, Valeant Pharmaceutical International Inc. deal

Cortex reacquired a portfolio of Ampakines for respiratory depression and related IP from Valeant. Valeant, which gained the assets through last year's merger with Biovail Corp. , discontinued the Ampakine program last November after it did...
BC Week In Review | Feb 7, 2011
Clinical News

CX1739: Phase II data

Top-line data from a double-blind, placebo-controlled Phase II trial in 20 adults with moderate to severe obstructive sleep apnea showed that a single oral dose of 900 mg CX1739 did not reduce mean apnea-hypopnea index...
BC Week In Review | Oct 11, 2010
Company News

Cortex Pharmaceuticals, Merck deal

Merck returned to Cortex rights to develop and commercialize Ampakine compounds to treat schizophrenia and depression as part of an ongoing prioritization process by the pharma. With additional funding, Cortex said it plans to start...
BC Week In Review | Apr 5, 2010
Company News

Biovail, Cortex Pharmaceuticals deal

Biovail Corp. (TSX:BVF; NYSE:BVF), Mississauga, Ontario   Cortex Pharmaceuticals Inc. (OTCBB:CORX), Irvine, Calif.   Business: Pulmonary, Hematology   Cortex sold Biovail's Biovail Laboratories International SRL subsidiary a portfolio of Ampakines and IP to treat respiratory...
BioCentury | Apr 6, 2009
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 12-mo op loss ended 12/31/08 1/9/09 Array BioPharma Inc. (NASDAQ:ARRY) 10% to ~350 $82.6 0.77 12/31/08 $53.9 (6-mo op loss ended 12/31/08) Seeking...
Items per page:
1 - 10 of 13